GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2000
Business Overview: Gilead is an independent biopharmaceutical company focused on infectious diseases and cancer. Key marketed products include AmBisome (antifungal), DaunoXome (Kaposi's Sarcoma), and VISTIDE (CMV retinitis). The company also holds a collaboration with Hoffmann-La Roche for Tamiflu (influenza).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 17% year-over-year for the nine-month period, driven primarily by a 14% increase in AmBisome product sales and a significant rise in royalty revenues from Roche (Tamiflu) and Fujisawa (AmBisome).
• Improved Profitability: Net loss narrowed significantly from $57.5 million to $27.5 million. Operating loss decreased from $60.1 million to $33.7 million.
• Debt Elimination: In August 2000, Gilead converted its entire $79.5 million balance of 6.25% convertible subordinated debentures into common stock, eliminating long-term debt and reducing interest expense.
• Expense Management: Selling, general, and administrative (SG&A) expenses decreased year-over-year, largely due to the absence of $18.2 million in merger-related expenses recorded in 1999. Research and development (R&D) expenses increased 11% due to Phase III trials for tenofovir and adefovir.
• Cash Flow: Net cash used in operating activities improved substantially, decreasing from $53.8 million in 1999 to $14.8 million in 2000.

Guidance, Outlook, and Risks

• Outlook: Management expects R&D expenses to remain elevated in the fourth quarter due to late-stage development of HIV and Hepatitis B candidates. SG&A expenses are expected to remain consistent with third-quarter levels.
• Stock Split: The Board approved an increase in authorized shares to facilitate a potential two-for-one stock split, anticipated in early 2001.
• Key Risks:
  • Regulatory: Potential rejection or delay of product approvals by the FDA or foreign agencies.
  • Market Acceptance: Reliance on AmBisome for a significant portion of operating income; competition from lower-priced products could reduce revenues.
  • Collaborations: Dependence on partners like Roche and Fujisawa for commercialization and revenue; disputes or lack of partner resources could adversely affect results.
  • Currency: Significant exposure to foreign currency fluctuations as most product sales are denominated in foreign currencies, while manufacturing costs are in U.S. Dollars.
• Unusual Items: Recognition of $3.5 million of a $7.0 million up-front licensing fee from EyeTech Pharmaceuticals in the first nine months of 2000. Discontinuation of the MiKasome development program in August 2000.

Investor Verification Checklist

• AmBisome Sales Trends: Verify the sustainability of AmBisome sales growth, which accounts for approximately 94% of product sales, amidst competitive pressures.
• Foreign Receivables: Review the status of past due accounts receivable in Greece, Spain, and Italy, which totaled $18.5 million (with $6.8 million over 120 days past due) as of September 30, 2000.
• Tamiflu Royalties: Monitor Roche's sales of Tamiflu and the timing of royalty recognition, noting that European marketing was delayed and royalties are recorded with a lag.
• R&D Pipeline: Assess the progress and potential regulatory outcomes for tenofovir (HIV) and adefovir (Hepatitis B), which are driving increased R&D spending.
• Liquidity Position: Confirm that the $293.2 million in cash and marketable securities remains sufficient to fund operations without immediate need for additional financing.